- Ambuja Cements‘ net income for 1Q 2024 is 5.7 billion rupees, beating the estimate of 5.19 billion rupees.
- Despite the beat, net income declined by 12% year-over-year (y/y).
- Revenue for the quarter is 45.2 billion rupees, which is 4.4% lower y/y and below the estimate of 47.38 billion rupees.
- Total costs increased by 2.7% y/y, reaching 41.6 billion rupees.
- Raw material costs decreased by 3.4% y/y to 5.41 billion rupees, significantly lower than the estimate of 8.02 billion rupees.
- Power and fuel expenses dropped by 22% y/y to 9.09 billion rupees, coming in below the estimate of 9.33 billion rupees.
- Other income saw a significant increase, rising to 4.20 billion rupees from 1.89 billion rupees y/y.
- Analyst recommendations include 26 buys, 7 holds, and 7 sells.
A look at Ambuja Cements Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts studying Ambuja Cements have given the company a positive long-term outlook based on a combination of Smartkarma Smart Scores. Ambuja Cements scores well in factors such as Resilience and Momentum, indicating strong stability and growth potential. With an overall balanced performance across Value, Dividend, and Growth scores, the company is positioned to maintain a solid standing in the cement manufacturing industry.
Ambuja Cements Limited, a leading cement manufacturer in India, is known for its robust operations and strategic market presence. The company’s focus on resilience and momentum, coupled with its domestic market strength and international subsidiary in Sri Lanka, paints a promising picture for its future growth and sustainability.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
